183 results
424B3
CRVO
CervoMed Inc
6 Jun 24
Prospectus supplement
6:03am
or an acceptable safety profile, gain regulatory approval, and become commercially viable. The Company has incurred net losses since its inception … neflamapimod (or any other drug candidate) for commercialization, the Company must demonstrate that it satisfies rigorous standards of safety
8-K
EX-4.2
lh6ftxdpcghk9
28 Mar 24
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
8:36am
8-K/A
EX-99.2
je0iwf5fxkfyvvef yb
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
8-K/A
EX-99.3
7dtn9b53dkpd3vt4v3
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
8-K
EX-3.5
7z3kmc6 1ocq0c4
17 Aug 23
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
4:15pm
8-K
50emayto5ero07f3li
17 Aug 23
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
4:15pm
425
EX-99.1
1cjg0v 2qy
14 Aug 23
Business combination disclosure
4:16pm
8-K
EX-99.1
4kuvqol
14 Aug 23
EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies
4:15pm
424B3
0ey0c29
13 Jul 23
Prospectus supplement
4:32pm
S-4/A
3p64t1 hwaq
22 Jun 23
Registration of securities issued in business combination transactions (amended)
9:46pm
CORRESP
eds3rvk76gm11cefsv
22 Jun 23
Correspondence with SEC
12:00am
UPLOAD
1ja2 g2qv0i
9 Jun 23
Letter from SEC
12:00am